Point72 Asset Management L.P. raised its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 105.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,756,122 shares of the biopharmaceutical company’s stock after acquiring an additional 1,413,722 shares during the […]
Point72 Asset Management L.P. lifted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 105.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,756,122 shares of the biopharmaceutical company’s stock after purchasing an additional 1,413,722 shares during the period. Point72 Asset Management L.P. […]
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) SVP Diane C. Young sold 45,000 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the transaction, the senior vice president now owns 2,115 shares […]
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) VP Elizabeth Crowley sold 15,000 shares of the firm’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $35.06, for a total transaction of $525,900.00. Following the completion of the transaction, the vice president now directly owns 9,074 shares […]
/PRNewswire/ DelveInsight s Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation.